Crystalys Therapeutics has dosed the first patients in a Phase 2 trial of dotinurad for the XOI intolerant, treatment failure gout population — a real but small cohort that the standard drugs never quite reach.
For the gout patient whose allopurinol stopped working — or whose body could not tolerate it in the first place — there is a clinical no-man's-land between a generic pill and an infusion suite. Crystalys Therapeutics announced on May 26, 2026 that it has dosed the first patients in AMETHYST, a U.S. Phase 2 trial of dotinurad, a once-daily oral URAT1 inhibitor, in people whose gout cannot be controlled by the standard xanthine oxidase inhibitors (XOIs) allopurinol and febuxostat. The launch is the first real clinical test of whether a next-generation selective URAT1 inhibitor — what Crystalys calls a "next-generation" approach — can serve a cohort that mainstream gout guidelines have never quite caught up with.
Most gout is manageable with cheap generics. Allopurinol, a xanthine oxidase inhibitor that blocks uric acid production, has been first-line standard of care for decades. When patients fail or cannot tolerate it, rheumatologists have historically had one further stop: pegloticase (Krystexxa), an infusible uricase therapy now owned by Amgen following its Horizon Therapeutics acquisition — a 2022 FDA label expansion allowed methotrexate co-administration to blunt immunogenicity.
Between those two rungs sits a population the Crystalys press release calls "difficult-to-treat" and that Crystalys CEO James Mackay, PhD, sized in a June 2026 GEN News feature at roughly 500,000 to 600,000 U.S. patients — those who have failed allopurinol, have been referred to a rheumatologist, and still have uncontrolled disease. He separately estimated that about 10% of U.S. gout patients, or roughly 1.5 million people, cannot tolerate xanthine oxidase inhibitors at all. Both figures are company commentary, not an independent market sizing, and should be read as the company's framing of the opportunity.
The clinical shape of that cohort is well-defined: hyperuricemia-driven inflammatory arthritis that does not respond to production-blocking drugs, or that flares through them, with the long-term risks of tophaceous deposits, joint damage and recurrent attacks.
Allopurinol and febuxostat work upstream: they stop the body from making uric acid. Pegloticase works downstream: it degrades uric acid in the blood. URAT1 inhibitors work in between, on the kidney's urate reabsorption machinery, helping the body clear more uric acid through urine.
Dotinurad is a once-daily, oral URAT1 inhibitor originally discovered by Japan's Fuji Yakuhin and approved in Japan in 2020. Crystalys holds U.S. and European rights through a 2025 licensing deal, per the company's announcement. The mechanistic pitch — what Crystalys calls a next-generation selective URAT1 profile — is that greater selectivity can avoid the kidney-safety signal that led AstraZeneca to withdraw lesinurad/Zurampic from the U.S. market in 2019, four years after its 2015 approval — a precedent that BioPharma Dive flagged as the safety bar any new URAT1 entrant must clear.
AMETHYST is registered as NCT07535034 on ClinicalTrials.gov. Per the Crystalys release and the GEN News interview, the trial is randomized, double-blind, placebo-controlled and multicenter, enrolling roughly 90 U.S. adults whose gout is either uncontrolled on a xanthine oxidase inhibitor or who cannot tolerate XOIs, or who have failed prior uricase therapy. The primary endpoint is the proportion of patients achieving serum uric acid below 6.0 mg/dL at Week 24, after a 24-week placebo-controlled period followed by a 12-week open-label active extension. Estimated primary completion is July 2027.
A first-patient-dosed event is a Phase 2 start, not an efficacy, regulatory or commercial milestone. The trial's question — whether dotinurad can move sUA under 6 mg/dL in a population already known to be hard to treat — is the right one to ask, and the data will not be available for roughly 18 months.
Crystalys is not alone in betting on the same gap. Sobi, which acquired Arthrosi in February 2026, reported positive topline Phase 3 results on May 21, 2026 for pozdeutinurad (formerly AR882), another once-daily oral next-generation URAT1 inhibitor, in the REDUCE 2 trial (NCT06439602). In Sobi's release, 69.2% of patients on the 75 mg arm and 56.6% on the 50 mg arm achieved serum uric acid below 6 mg/dL at month 6, versus 8.1% on placebo (p < 0.0001), in 811 patients over a 12-month placebo-controlled period. Safety was consistent with prior studies; full efficacy, flare and tophus data are slated for a Q4 2026 congress. Sobi's companion Phase 3 REDUCE 1 is fully enrolled with data expected in the second half of 2026.
The two programs are at very different stages — a Phase 2 start against a fully enrolled Phase 3 topline — and there is no head-to-head data. Any "best-in-class" or "next-generation" claim is, for now, a company framing, not an established comparison. The BioPharma Dive coverage of Arthrosi's $153 million Series E in late 2025 underscored how crowded the URAT1 lane has become, with additional China-based programs in the clinic as well.
Gout is the most common inflammatory arthritis and is driven by sustained hyperuricemia. Prevalence was estimated at roughly 55.8 million people worldwide in 2020, up 22.5% from 1990, and is widely projected to continue rising with aging populations and the growing prevalence of obesity, hypertension and chronic kidney disease — the metabolic conditions that share risk factors with hyperuricemia. The harder-to-treat tail is small relative to total prevalence, but it is the cohort that drives specialist referrals, recurrent emergency visits and long-term joint damage.
AMETHYST's readout in mid-2027 will be the first datapoint on whether dotinurad can move sUA in a genuinely refractory population at the doses and duration Crystalys is testing. REDUCE 1's full data later this year, and REDUCE 2's detailed congress presentation in Q4 2026, will set the bar for the class. Until then, the "next-generation URAT1" label is a hypothesis both companies are asking the data to settle, not a conclusion the field has reached.